In a high-stakes move to redefine the standard of care for stroke rehabilitation, Mobia Medical—the innovator behind the Vivistim neurostimulation system—officially joined the public markets this past Friday. The medtech startup, which aims to unlock new recovery potential for millions of stroke survivors, successfully raised approximately $150 million in its initial public offering (IPO). However, the company’s first day on the exchange was met with investor skepticism, as shares tumbled 21% from their $15 offer price to close at $11.75.
Despite the volatile market reception, leadership at Mobia remains steadfast, positioning the capital infusion as a critical bridge toward achieving widespread clinical adoption of their groundbreaking technology.
The Core Innovation: Vivistim and the Vagus Nerve
At the heart of Mobia’s value proposition is the Vivistim device, a pioneering neurostimulation system that targets the vagus nerve to enhance upper limb motor function. For the roughly 9 million stroke survivors currently living in the United States, many face long-term physical impairment that resists conventional therapy.
Vivistim, which received FDA approval in 2021 and entered the commercial market in 2023, represents a significant leap forward. The treatment protocol involves a surgical implantation of the device, followed by a collaborative regimen where patients engage in physical therapy exercises. During these sessions, the device delivers precise stimulation to the vagus nerve, which neurologists believe primes the brain to "rewire" itself, facilitating the recovery of hand and arm movement that might otherwise be considered permanent.
Currently, Mobia holds a unique position in the medtech landscape, serving as the only FDA-approved solution specifically indicated for chronic ischemic stroke survivors who suffer from moderate to severe upper extremity impairment. By addressing this specific, underserved patient population, Mobia aims to transform the rehabilitation paradigm.
Chronology: From Clinical Validation to Public Entity
The journey of Mobia Medical—formerly known as MicroTransponder—is a testament to the rigorous, multi-year path required to bring high-risk, high-reward medical devices to market.
- Pre-2021: The company operated under the MicroTransponder banner, conducting extensive research and clinical trials to prove the efficacy of vagus nerve stimulation in post-stroke recovery.
- 2021 (The Lancet Study): A pivotal moment arrived with the publication of a randomized, controlled trial in The Lancet. The study, which included 108 participants, demonstrated that nearly 50% of those receiving Vivistim treatment achieved a clinically meaningful improvement in arm function, compared to just 24% in the control group. Crucially, the participants were, on average, three years post-stroke, suggesting that recovery is possible long after the initial injury.
- 2021 (Regulatory Milestone): Following the success of their clinical data, the FDA granted approval for the Vivistim system, marking a turning point for the company’s trajectory.
- 2023 (Commercial Launch): The company officially transitioned from a research-heavy entity to a commercial one, beginning the rollout of Vivistim across the U.S.
- 2025 (Public Offering): After demonstrating a trajectory of revenue growth, Mobia opted for an IPO to fund its aggressive commercial expansion and further market penetration.
Financial Performance and Investor Sentiment
The company’s path to the public markets is underscored by a classic "growth-at-a-cost" narrative. In their recent SEC filings, Mobia reported a significant widening of its net loss, jumping from $24.6 million in 2024 to $46.5 million in 2025.
However, the revenue figures paint a more optimistic picture of the company’s market traction. Mobia more than doubled its annual revenue during that same period, surging from $15.6 million in 2024 to $32 million in 2025. This rapid revenue acceleration suggests that while the company is currently burning capital to establish a footprint, the product-market fit is robust.
CEO Richard Foust has downplayed the market’s immediate reaction, emphasizing that the IPO was never about short-term price action, but rather about long-term capacity building. Foust noted that the capital raised provides the necessary fuel to scale, particularly in the face of what he describes as a "really large unmet market."
Strategic Implications: Expanding the Footprint
Mobia’s roadmap for the coming quarters is clear: increase access, boost awareness, and normalize the therapy.
Commercial Expansion
Currently, the company employs roughly 40 territory managers across the United States. A significant portion of the IPO proceeds is earmarked for a planned commercial expansion, which will include hiring more personnel to act as clinical liaisons. The goal is to ensure that stroke centers and rehabilitation hospitals are not only aware of the technology but are also trained to implement it seamlessly.
Bridging the Gap in Awareness
Perhaps the most significant challenge for Mobia is education. Many primary care physicians and even some specialists remain unaware that an FDA-approved, implantable solution exists for chronic stroke survivors. Foust expressed a desire to shift the conversation, urging medical professionals to consider Vivistim as a "frontline therapy" rather than a last resort.
To achieve this, the company intends to:
- Engage Medical Societies: Strengthening ties with neurology and rehabilitation boards to foster clinical consensus.
- Collaborate with Payers: Working to ensure that insurance coverage expands, lowering the financial barriers for patients seeking the treatment.
- Direct-to-Physician Education: Moving beyond specialized stroke centers to reach the broader network of primary care providers who are often the first to evaluate a patient’s long-term recovery prospects.
The Broader Medtech Context
Mobia’s entry into the public sphere occurs within a broader, somewhat cautious, medtech IPO environment. While the market for medical devices remains vital, it has been characterized by selective investment.
Recent precedents include Medtronic’s spin-off of its diabetes division, MiniMed, which went public earlier this year, raising $560 million. Other notable entrants, such as Heartflow ($364 million) and Beta Bionics ($204 million), have demonstrated that investors are still willing to back companies with clear, validated technologies that address chronic health conditions.
Mobia’s decision to go public despite a "volatile stock market," as Foust described it, indicates a high degree of confidence from the board and institutional investors. By moving to the public market now, Mobia is signaling that it is prepared to transition from a venture-backed startup to a permanent fixture in the neurological care ecosystem.
Future Outlook: Creating Operating Leverage
When asked about the path to profitability, Foust remained optimistic. The strategy is to leverage the company’s increasing revenue to achieve economies of scale. As the volume of implants increases, the cost per unit and the cost of supporting clinical training are expected to normalize, providing the "operating leverage" needed to turn the corner on net losses.
"What makes us excited about this journey and getting access to this capital is we now know how many more patients we will be able to treat," Foust said.
For the millions of stroke survivors who have long been told that their recovery plateaued months after their incident, Mobia’s technology offers a new, albeit surgical, avenue for hope. Whether the public markets will reward this vision remains to be seen, but for Mobia, the race to make Vivistim a standard of care has only just begun. The focus is no longer just on clinical validation, but on clinical saturation—turning a breakthrough device into a household name for stroke recovery.
